The Exubrion Therapeutics® Team
A seasoned team of managers and directors
Our leadership team brings a broad range of experience in various disciplines, including animal health and nuclear medicine.
Laurie A. McRay, CPA, CFE
Executive Chair & Interim CEO
Laurie has over 25 years of experience as the CEO & Founder of Aquinas Advisors, LLC, her Fiduciary Investment & Wealth Management Firm. She specializes in biomedical technology private equity investment.
Laurie is focused on the novel radioisotope technology, Tin-117m, commercialized by Exubrion Therapeutics. This technology represents a quantum leap forward in the treatment of canine and equine OA and has enormous potential as a future human therapy not only for OA, but also certain cancers, Alzheimer’s Disease (AD), and heart disease.
She holds a BBA in Accounting from the University of Texas at Austin and has completed the Global Private Equity Programme at Oxford University. She is also pursuing a law degree from the University of London.
Until recently, Laurie shared her life with Claudia, a Yorkipoo who was found as a stray and who later went everywhere with her Mom, flying in first-class style in her own Delta travel carrier.
“These are exciting times at Exubrion Therapeutics. We’re harnessing next gen technology that’s literally light years ahead of what’s currently available for treating osteoarthritis (OA) in animals. In fact, we’re changing the future of what’s possible in canine and equine OA… and even looking beyond to multiple human applications.”
Synoventin OA
Jenn Kirk
Chief Executive Officer
(effective May 3rd, 2025)
Jennifer (Jenn) Kirk has more than 28 years of experience as a business leader with strong financial and operations acumen. She has a proven track record of building great teams, delivering results, and creating value.
Jenn comes to Exubrion from Medtronic Inc., where she was Sr Finance Executive. Prior to that, she was Sr Vice President, Integration and Value Capture for Occidental Petroleum.
A certified public accountant, Jenn holds a BS in economics from the University of California and an MBA from California State University. She received her Cyber Risk Oversight Program Certification from Carnegie Mellon and recently completed her certification at Harvard Business School for Leading Global companies and Making Corporate Boards More Efficient.
Jenn, her husband, and 3 daughters share their lives with Bubbles (Jenn’s 4th “daughter”), a rescue mix breed dog, and Goober, a thoroughbred rescued from slaughter who smiles on command.
“Animal health and pain management are deeply important because our pets rely on us to ensure they live comfortable, happy lives. Pain can rob them of their mobility, energy, and even their spirit. At Exubrion, we are dedicated to changing that.”
Synoventin OA
Eric Schreiber
Chief Commercial Officer
Eric heads up marketing, advertising, and sales at Exubrion, bringing 30 years of experience in these disciplines to the team.
He holds a BS in Business Administration from Bucknell University and has completed executive education programs at Wharton and Kellogg.
Eric is the pet parent of Xander, an English Labrador retriever.
“I thrive on the excitement of bringing new technologies to market and seeing their effect on improving the quality of life for pets, pet parents, and veterinarians.”
Synoventin OA
Nigel Stevenson, BSc, PhD
Chief Operating Officer
Nigel works as the operations lead at Exubrion and brings a long history in physics, nuclear physics, and radioisotope research and development to the role. Nigel has held senior positions in several radioisotope manufacturing and research companies in addition to academic roles at National Laboratories. He has over 90 publications and more than 30 patents in this field. He is the Immediate Past President of the World Council on Isotopes.
Nigel holds a BSc in physics and a PhD in nuclear physics from The University of London, U.K.
Nigel is the pet parent of Zoe and Angel, both Pomeranians, his most recent of many beloved dogs.
“As a lifelong dog parent, I sympathize with dogs that suffer from painful conditions and strongly desire to provide a solution that alleviates this.”
Synoventin OA
Bob Menardi, DVM
Chief Veterinary Officer
Robert Menardi DVM, is Chief Veterinary Officer with Exubrion Therapeutics. He leads the company’s comprehensive veterinary technical education and outreach programs, and serves as the subject matter expert for members of the veterinary profession. He frequently consults with clinical and academic veterinarians on the use of radiosynoviorthesis for treatment of osteoarthritis. He also heads the pharmacovigilance functions at Exubrion Therapeutics.
Dr. Menardi worked in private clinical practice for 12 years after graduating from Colorado State University in 1990 with his DVM degree. Prior to joining Exubrion, Dr. Menardi served in multiple leadership roles in the animal health industry. Since 2002, his areas of responsibility have included technical marketing, field veterinary services, veterinary operations and professional development, biologics marketing, and pharmacovigilance.
Dr. Menardi is a pet parent to Romeo, a geriatric Schnauzer, Starla, a young Australian Shepherd whose main goal in life is to antagonize the schnauzer, and Echo, a Green-cheeked Conure parrot, who is definitely the alpha member of the household.
“I have seen firsthand the toll that chronic pain can take from our pets and their families. Being able to offer workable solutions is one of my most important goals as a veterinarian.”
Synoventin OA
Timothy Corbin
Production Manager
Tim works as the production manager for Exubrion Therapeutics and brings over 25 years of manufacturing experience in the medical device and pharmaceutical industries to the team.
Tim holds a BS in Biochemistry and Chemistry from the University of Georgia.
Tim is the pet parent to 2 dogs: Hank and Dolly, litter mates that are a Chihuahua mix, as well as a cat: Kixie, a yellow tabby.
“I was taught at an early age that my pets’ welfare came first. If I was hungry and thirsty, I fed and watered my pets before I ate or drank. It excites me to know that we are providing pain relief to animals that do not understand their pain.”
Synoventin OA
Anita Jarrard
Director of Administration
Anita leads the organizational functions at Exubrion and brings over 25 years of executive administration experience to the team. Prior to joining Exubrion, she spent 23 years in the big data industry working with top executives at Equifax and LexisNexis.
She holds a BS in business management from the University of Georgia.
Anita is the pet parent of a 6-lb. teacup Yorkie named Trixie, whom she is happy to let rule the home.
“My father instilled the words of Arthur Schopenhauer in my heart: ‘Compassion for animals is intimately associated with goodness of character, and it may be confidently asserted that he who is cruel to animals cannot be a good man.’”